NTLA earnings call for the period ending June 30, 2019.
News & Analysis: Intellia Therapeutics
The CRISPR pioneer is taking a slow-and-steady approach to drug development. If peers are overlooking one key element of gene editing, that approach could pay off.
The gene-editing approach might prove more useful outside the clinic.
The field expanded into a new therapeutic area, and fell back into a bitter dispute over intellectual property.
Two biotechs that don't have approved drugs yet. One clear winner.
First-quarter earnings results from three gene-editing companies gave Wall Street analysts pause.
NTLA earnings call for the period ending March 31, 2019.
The future of treating disease might be gene editing, and these five stocks have the most promising technologies.
Which stock wins in a matchup between two leading gene-editing biotechs?
The future of medicine involves the precise engineering of human cells. Turns out, that future may not include that promising CRISPR technique.